

Direct-to-consumer tests: emerging trends are cause for concern

Emma Grundtvig Gram,^{1,2} Tessa Copp,^{2,3} David F Ransohoff,⁴ Annette Plüddemann,⁵ Barnett S Kramer,² Steven Woloshin,^{2,6} research Patti Shih,⁷

¹ Center of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

² Lisa Schwartz Foundation for Truth in Medicine, Norwich, VT, USA

³ Faculty of Medicine and Health, School of Public Health, University of Sydney, Sydney, Australia

⁴ Division of Gastroenterology and Hepatology, Departments of Medicine and Epidemiology, University of North Carolina, Chapel Hill, USA

⁵ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

⁶ Center for Medicine and Media, Dartmouth Institute, Lebanon, USA

⁷ Australian Centre for Health Engagement Evidence and Values, School of Health and Society, University of Wollongong, Wollongong, Australia

Correspondence to: Patti Shih pshih@uow.edu.au

Emma Gram and colleagues argue that the public needs high quality information and effective communication about the evidence behind the marketing of direct-to-consumer tests

Advances in diagnostic technology and digital health have increased the variety and volume of direct-to-consumer tests—commercial tests initiated by consumers without clinical consultation.¹ Sales of these tests have surged from \$15m in 2010 to \$1.15bn in 2022 in the United States alone.⁷⁻⁹ As well as the better known DTC tests for covid-19, genetics, and HIV, many other types of tests are now available, including for prostate health checks, thyroid function, and food sensitivity.^{6 10-12} However, no dedicated regulatory framework exists to govern the appropriate use of DTC emerging products. Although DTC tests offer consumers more choice, accessibility, and privacy,¹⁻³ qualitative studies show that users have found decisions on selecting and purchasing tests a challenge.³ Concerningly, companies use persuasive marketing techniques such as narratives of “women’s empowerment” to promote non-evidence based health interventions.^{6 12 15} As DTC tests are promoted to broad populations rather than specific groups for which there is evidence of improved health outcomes, consumers are at risk of buying products that do more harm than good. Therefore, availability of DTC tests can trigger unnecessary and inappropriate use.⁴⁻⁶ Indeed, a qualitative study suggests that some users of DTC tests were motivated to repeat testing to seek regular reassurance, whereas others who received abnormal results did not follow-up with a general practitioner.¹⁴ Better information and regulation are essential to protect consumers from potential harms.

Poor accuracy and misleading consumer information

Diagnostic home self-testing kits are increasingly available for consumers to purchase at pharmacies, supermarkets, and online.¹⁶ Government survey data suggest that in January 2022, during the peak of the covid-19 pandemic, 175 million rapid antigen tests were taken across England.¹⁷ Reported reasons for testing included informing health

self-management strategies (eg, home quarantining) and peace of mind.¹⁷ Familiarity with rapid antigen tests during the pandemic has triggered uptake of other types of home self-testing.¹⁸ However, a systematic review of the accuracy of self-diagnosis tests for common conditions found an overall poor accuracy of the tests or the interpretation of the results.¹³ The Royal College of Obstetricians and Gynaecologists (UK) recommends against over-the-counter tests measuring urine follicle stimulating hormone levels to detect menopause because of their poor accuracy.¹⁹ False positive and false negative results may provide incorrect or misleading information to women regarding fertility or symptoms (box 1). Similarly, the anti-Müllerian hormone test is often advertised for predicting the chance of conceiving,⁵ a claim not supported by evidence, and may give women false reassurance or lead them to expedite pregnancy plans.²⁰

The accuracy of HIV self-testing is also problematic. A systematic review found point-of-care salivary HIV tests had a pooled sensitivity of 92.8% (95% confidence interval 86% to 96.5%) and specificity of 99.8% (99.1% to 99.9%).¹³ This is not sufficiently accurate to rule out infection, particularly given the harmful consequences of false reassurance and delayed access to care triggered by false negative results.²¹ On the other hand, false positive results can potentially overburden the healthcare system as they cause unnecessary follow-up consultations and confirmatory testing.²² Therefore, consumers need clear instructions on how to interpret tests in specific contexts and test probabilities.²³

The information provided in enclosed instructions, packaging, and advertising is also an important resource used by consumers for informed decision making, yet this is sometimes incomplete, misleading, or even false.^{5 15 24} For example, advertising of covid-19 tests often lacked information about risks of false results, thus overemphasising the trustworthiness of the tests.²⁴ A randomised trial showed that people using rapid antigen tests for covid-19 misinterpreted the implications of the results and failed to follow official instructions on response.²³

Clinical tests repurposed for assessing “wellness”

A recent review showed that more than 40% of DTC tests marketed online in Australia were sold as “health checks.”⁶ These included tests of hormone levels, nutritional profiles measuring trace elements, and full blood count, which are usually used in clinical settings and lack evidence of benefit in asymptomatic healthy populations.²⁵ Although “health checks” can provide a one-off indicator of whether biometric markers are inside or outside the “normal” range, they do not indicate if and how these results may be clinically meaningful and may carry important harms (box 1).

Box 1: Potential harms of direct-to consumer tests

Poor accuracy of home testing kits and misleading consumer information

- False positive results: psychosocial distress, pressure to have health interventions or treatment, overtreatment
- False negative results: false reassurance, delayed access to care, additional transmissions (in case of infectious diseases)
- Misleading information: harms arising from misinformed healthcare decisions: false hope about promises of tests, failing to act appropriately on tests results

Tests used in clinical settings repurposed for assessing “wellness”

- Results may trigger downstream (over)testing or lead to unnecessary (over)use of non-evidence based supplements and treatments with associated costs
- Unnecessary medicalisation of healthy populations—labelling and psychosocial distress associated with abnormal results that are not clinically important
- Digital health inequalities

Premature marketing of multicancer detection tests

- Increased detection of late stage cancer without improvement in mortality or morbidity (earlier but ineffective diagnosis) does not benefit consumers
- Increased healthcare system costs through overdiagnosis, overtreatment, and false positive results

An example is testosterone tests, which are commonly used in the clinical setting to detect endocrinological conditions.²⁶ Testosterone tests sold direct to consumers most often target men following recreational fitness regimens, especially bodybuilders, for “optimising” testosterone levels. The concern is that testosterone tests can be misused to justify unsafe supplementation and testosterone replacement therapy, which is now also commercially available.²⁷⁻²⁹ Some companies offer subscriptions to hormone tests, triggering repeat testing to monitor the outcome of the recommended supplements or regimens. From 2017 to 2019, there was a 1688% increase in visitors to DTC prescribing and pharmacy websites offering treatment for erectile dysfunction, **reaching almost five million a month**³⁰ and sales of testosterone now account for more than \$400m in the US.^{31 32} The American Urological Association recommends that patients are informed about the long-term side effects of testosterone replacement, such as infertility,³³ and the FDA has issued a caution about non-clinical use of testosterone products because of the increased risk of major adverse cardiovascular outcomes.³⁴ Targeting healthy populations creates an entirely new and potentially lucrative market for test manufacturers but risks medicalisation. However, the health status of healthy people cannot be reliably measured with testing because, without clinical indications or context, there are no agreed protocols or harmonised reference intervals to interpret whether the results fall into a healthy or pathological range for the individual.⁶ The pre-test probability is low in healthy populations,³⁵ and testing increases the chance of false-positive results and overdiagnosis.³⁶ However, regulation of DTC health checks is challenging as many of these products are labelled as “not for medical purposes,” thus circumventing in vitro diagnostic regulation and laboratory quality assurance processes that are primarily targeted at tests used in patient care.

Premature marketing of multicancer detection tests

Multicancer early detection tests are a recently developed technology aiming to detect multiple cancers before symptoms have occurred, including cancers for which there are no specific screening tests. Multicancer tests measure various substances such as abnormal DNA and use complicated proprietary algorithms to derive metrics that indicate the likelihood of cancer and likely tissues of origin.³⁷

These tests are currently being marketed and sold in the US without any evidence of reduced mortality and extension of life expectancy (box 1.). Consumers can request the test through their healthcare provider or through a telemedicine portal. The US

Preventive Services Task Force recommends screening for four cancers—breast, cervical, colon, and lung—using cancer specific tests.³⁸ The multicancer tests are designed to detect over 50 types of cancer and are thus inconsistent with current guidelines.³⁹ Nevertheless, NHS England has announced the purchase of a million of these tests.⁴⁰

In the largest screening study reported to date, over 6000 subjects in seven US medical centres were followed up for one year after having a multicancer test.⁴¹ The sensitivity of the test increases with the stage of the cancer, as small cancers shed fewer, harder to detect fragments of abnormal DNA than larger cancers. Thus, these tests are more likely to detect cancers at advanced stages, limiting their benefits. In addition, the study did not have a comparison group or adequate follow-up and provided no information on whether it prevents more deaths or on the risks of overdiagnosis and overtreatment.⁴¹ An important problem of multicancer tests is that the harms of finding advanced stage cancer “earlier” could be substantial. Although the cancer is detected and treated, the toxicity, morbidity, and financial burdens associated with earlier, but not more effective, treatment may outweigh any benefits. In the 6000 subjects, 19 solid tumours were detected, 10 of which were cancers for which standard screening programmes are already implemented and all were late stage (III or IV).⁴¹ Furthermore, in 62% (57/92) of participants who had a positive cancer signal, the results were false positives. Invasive procedures were conducted on 88% and workup leading to diagnostic resolution spanned two to eight months. In other words, many people went through unnecessary diagnostic investigation with potential associated costs and anxiety.

Potential benefits of consumer tests

Using DTC tests may be beneficial in some cases. For people with symptoms that warrant investigation or in populations with high prevalence and undertesting, the accessibility and privacy offered by DTC tests may outweigh the limitations posed by low accuracy. One example is sexually transmitted infections.^{42 43} Even if accuracy is only modest, HIV self-testing might have a high positive predictive value in settings with high prevalence.⁴⁴

Some DTC tests might empower consumers by providing better access and responding to prominent gaps in the healthcare system. Consumers have reported using DTC tests when general practice appointments are difficult to arrange because of cost, distance, and lengthy waiting times.⁴ When consumers felt dismissed by GPs, they used self-testing to justify their need to seek clinical care.⁴ However, few studies look beyond the initial access aspect of DTC testing and are yet to demonstrate that their use leads to better health outcomes.

Need for effective management of DTC tests

Despite the promises of new technologies and care models, the marketing of DTC tests often outpaces supporting evidence of health outcomes and clinical value, especially when targeting healthy consumers, who are least likely to benefit from testing. As such, some testing is done because it is technically possible rather than because it is useful.⁴⁶ To address potential consumer harms,⁴⁷ professional organisations are calling for action. The UK Royal College of General Practitioners (RCGP) states that tests must have clear interpretations and results, tests should include complete information, and patients need to have clear information about when self-testing is recommended and

when it is not.⁴⁸ The European Federation for Laboratory Medicine and Clinical Chemistry taskforce on DTC tests makes similar recommendations and urges involvement of laboratory professionals in supporting consumer decision making about using DTC tests.¹ However, without official policy directives and regulation of commercial suppliers that operate outside the healthcare system, these changes are slow to happen.

Currently, most jurisdictions do not have clear definitions, clinical guidelines, or dedicated regulatory frameworks for DTC tests.⁴⁹ Although most home self-testing kits are regulated under in vitro devices regulation, the focus is primarily on quality and efficacy of the devices rather than on appropriateness of test selection and use. Some jurisdictions do require post-market surveillance, but it is insufficient to mitigate the range of potential harms. For example, in England the Care Quality Commission oversees healthcare providers who perform tests and analysis but has no remit for marketing or consumer self-tests.²² The same goes for the US Food and Drug Administration, which oversees and reviews DTC tests only for high risk medical purposes. There are few guidelines about appropriate use of DTC tests processed in laboratories, including non-medical laboratories, where most wellness tests and non-evidence based tests take place.¹

Clearly, current regulatory frameworks are inadequate in responding to the new ways in which DTC tests are being sold and used. A dedicated regulatory framework should be established for DTC tests that has a focus on supporting consumers as decision makers, rather than leaving regulation of different types of tests ancillary to in vitro diagnostic regulation or laboratory accreditation.¹ Importantly, FDA and other regulators must pay particular attention to DTC tests marketed for wellness purposes and analysed in non-medical laboratories.

The Preventing Overdiagnosis Scientific Committee has called for transparent communication in DTC testing.⁵⁰ Commercial suppliers should prove product benefit for their consumers, including clearly defining appropriate targeted populations of tests to avoid harmful misinterpretation. In addition, industry and regulatory bodies should engage in broader concepts of harm such as financial burden, psychological and physical harm, overdiagnosis, and ineffective diagnosis associated with DTC testing. These harms should be better recognised and studied as DTC medicine becomes more popular as an alternative model of care.^{51 52} In addition, more research on consumers' perspectives and values in self-testing is critical for improving user centred practice, benefit, and safety.

Key messages

Medical tests marketed and sold directly to consumers may help people make personal health decisions and enhance consumer autonomy

Inappropriate use of such tests can pose harm to consumers through unnecessary treatment or overdiagnosis

The public needs high quality evidence, effective communication about the evidence, and equitable access to tests with important health benefits

Regulatory bodies must ensure and enforce transparent communication to protect consumers from unbalanced and misleading marketing

Contributors and sources: This article is based on a session at the preventing overdiagnosis conference designed and conducted by the authors. PS does research on direct-to-consumer healthcare and health-consumer engagement in policy. AP's research aims to identify and assess the evidence for diagnostic tests and technologies. DFR's research focuses on methods for evaluating diagnostic tests, particularly screening. He has served in advisory roles to NCI, FDA, and US Preventive Services Task Force. EG and PS drafted the manuscript and all authors contributed intellectually to the development and revision. PS is the guarantor.

Public and patient involvement: AP presented the work on the evidence for and public advertisement of direct-to-consumer testing at a public seminar at the University of Oxford to gather the views on these tests from members of the public. The discussion session at this seminar informed and refined the research questions and issues that need addressing. based on the test results.

Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following: AP holds grant funding from the NIHR School for Primary Care Research; DR reports consultancy fees from Mercy Bioanalytics and the National Cancer Institute for advisory work in discovery research on cancer screening tests; EGG, BSK, and SW are current members of the scientific committee for Preventing Overdiagnosis, for which they receive no financial support.

Provenance and peer review: Commissioned; externally peer reviewed.

References:

<jrn>1 Shih P, Sandberg S, Balla J, et al. Direct-to-consumer testing as consumer initiated testing: compromises to the testing process and opportunities for quality improvement. *Clin Chem Lab Med* 2024;14. [PubMed doi:10.1515/cclm-2024-0876](https://pubmed.ncbi.nlm.nih.gov/doi/10.1515/cclm-2024-0876)</jrn>

<jrn>2 Exten C, Pinto CN, Gaynor AM, Meyerson B, Griner SB, Van Der Pol B; Board of Directors of the American Sexually Transmitted Diseases Association. Direct-to-consumer sexually transmitted infection testing services: a position statement from the American Sexually Transmitted Diseases Association. *Sex Transm Dis* 2021;48:e155-9. [PubMed doi:10.1097/OLQ.0000000000001475](https://pubmed.ncbi.nlm.nih.gov/doi/10.1097/OLQ.0000000000001475)</jrn>

<jrn>3 den Oudendammer WM, Broerse JEW. Towards a decision aid for self-tests: users' experiences in the Netherlands. *Health Expect* 2019;22:983-92. [PubMed doi:10.1111/hex.12903](https://pubmed.ncbi.nlm.nih.gov/doi/10.1111/hex.12903)</jrn>

<jrn>4 Ryan A, Ives J, Wilson S, Greenfield S. Why members of the public self-test: an interview study. *Fam Pract* 2010;27:570-81. [PubMed doi:10.1093/fampra/cmq043](https://pubmed.ncbi.nlm.nih.gov/doi/10.1093/fampra/cmq043)</jrn>

<jrn>5 Johnson A, Thompson R, Nickel B, Shih P, Hammarberg K, Copp T. Websites selling direct-to-consumer anti-mullerian hormone tests. *JAMA Netw Open* 2023;6:e2330192. [PubMed doi:10.1001/jamanetworkopen.2023.30192](https://pubmed.ncbi.nlm.nih.gov/doi/10.1001/jamanetworkopen.2023.30192)</jrn>

<jrn>6 Shih P, Ding P, Carter SM, et al. Direct-to-consumer tests advertised online in Australia and their implications for medical overuse: systematic online review and a typology of clinical utility. *BMJ Open* 2023;13:e074205. [PubMed doi:10.1136/bmjopen-2023-074205](https://pubmed.ncbi.nlm.nih.gov/doi/10.1136/bmjopen-2023-074205)</jrn>

<jrn>7 Schwartz LM, Woloshin S. Medical marketing in the United States, 1997-2016. *JAMA* 2019;321:80-96. [PubMed doi:10.1001/jama.2018.19320](https://pubmed.ncbi.nlm.nih.gov/doi/10.1001/jama.2018.19320)</jrn>

- <eref>8 Keshavan M. These are the key players in the home health testing market. MedCity News. 20 Jan 2016. <https://medcitynews.com/2016/01/20-key-players-in-the-direct-to-consumer-lab-testing-market/> </eref>
- <eref>9 Precedence Research. Direct-to-consumer laboratory testing market size 2023-2032. 2023. <https://www.precedenceresearch.com/direct-to-consumer-laboratory-testing-market></eref>
- <jrn>10 Ryan A, Wilson S, Greenfield S, Clifford S, McManus RJ, Pattison HM. Range of self-tests available to buy in the United Kingdom: an internet survey. *J Public Health (Oxf)* 2006;28:370-4. [PubMed doi:10.1093/pubmed/fdl051](https://pubmed.ncbi.nlm.nih.gov/10.1093/pubmed/fdl051/)</jrn>
- <jrn>11 Lovett KM, Mackey TK, Liang BA. Evaluating the evidence: direct-to-consumer screening tests advertised online. *J Med Screen* 2012;19:141-53. [PubMed doi:10.1258/jms.2012.012025](https://pubmed.ncbi.nlm.nih.gov/10.1258/jms.2012.012025/)</jrn>
- <jrn>12 Wong AWY, White HEG, Plant A, Shipman AR, Shipman KE. Issues surrounding consumer-bought food-allergy testing. *Clin Exp Dermatol* 2022;47:547-52. [PubMed doi:10.1111/ced.14978](https://pubmed.ncbi.nlm.nih.gov/10.1111/ced.14978/)</jrn>
- <jrn>13 McLellan J, Heneghan C, Roberts N, Pluddemann A. Accuracy of self-diagnosis in conditions commonly managed in primary care: diagnostic accuracy systematic review and meta-analysis. *BMJ Open* 2023;13:e065748. [PubMed doi:10.1136/bmjopen-2022-065748](https://pubmed.ncbi.nlm.nih.gov/10.1136/bmjopen-2022-065748/)</jrn>
- <jrn>14 Ickenroth MHP, Grispen JEJ, Ronda G, et al. Motivation and experiences of self-testers regarding tests for cardiovascular risk factors. *Health Expect* 2014;17:60-72. [PubMed doi:10.1111/j.1369-7625.2011.00733.x](https://pubmed.ncbi.nlm.nih.gov/10.1111/j.1369-7625.2011.00733.x/)</jrn>
- <jrn>15 Copp T, Pickles K, Smith J, et al. Marketing empowerment: how corporations co-opt feminist narratives to promote non-evidence based health interventions. *BMJ* 2024;384:e076710. [PubMed doi:10.1136/bmj-2023-076710](https://pubmed.ncbi.nlm.nih.gov/10.1136/bmj-2023-076710/)</jrn>
- <eref>16 Parr E. GP workload warning as Tesco starts selling at-home testing range. Pulse. 27 Mar 2023. <https://www.pulsetoday.co.uk/news/clinical-areas/womens-health/gp-workload-warning-as-tesco-starts-selling-at-home-testing-range> (accessed 11 March 2024)</eref>
- <eref>17 UK Government. COVID-19: general public testing behaviours. GOV.UK. <https://www.gov.uk/government/publications/lfed-tests-how-and-why-they-were-used-during-the-pandemic/covid-19-general-public-testing-behaviours></eref>
- <jrn>18 Mahase E. Pandemic self-testing has led to boom in unregulated “wellness” tests, researchers warn. *BMJ* 2023;382:p1895. [PubMed doi:10.1136/bmj.p1895](https://pubmed.ncbi.nlm.nih.gov/10.1136/bmj.p1895/)</jrn>
- <eref>19 RCOG. RCOG recommends against using over-the-counter menopause tests. 2022. <https://www.rcog.org.uk/news/rcog-recommends-against-using-over-the-counter-menopause-tests/> (accessed 20 March 2024)</eref>
- <jrn>20 Copp T, Thompson R, Doust J, et al. Community awareness and use of anti-Müllerian hormone testing in Australia: a population survey of women. *Hum Reprod* 2023;38:1571-7. [PubMed doi:10.1093/humrep/dead111](https://pubmed.ncbi.nlm.nih.gov/10.1093/humrep/dead111/)</jrn>
- <jrn>21 Mourez T, Lemée V, Delbos V, et al. HIV rapid screening tests and self-tests: Be aware of differences in performance and cautious of vendors. *EBioMedicine* 2018;37:382-91. [PubMed doi:10.1016/j.ebiom.2018.10.012](https://pubmed.ncbi.nlm.nih.gov/10.1016/j.ebiom.2018.10.012/)</jrn>
- <jrn>22 Wilkinson E. The rise of direct-to-consumer testing: is the NHS paying the price? *BMJ* 2022;379:o2518. [PubMed doi:10.1136/bmj.o2518](https://pubmed.ncbi.nlm.nih.gov/10.1136/bmj.o2518/)</jrn>

- <jrn>23 Woloshin S, Dewitt B, Krishnamurti T, Fischhoff B. Assessing how consumers interpret and act on results from at-home covid-19 self-test kits: a randomized clinical trial. *JAMA Intern Med* 2022;182:332-41. [PubMed doi:10.1001/jamainternmed.2021.8075](#)</jrn>
- <jrn>24 Taylor-Phillips S, Berhane S, Sitch AJ, et al. Information given by websites selling home self-sampling COVID-19 tests: an analysis of accuracy and completeness. *BMJ Open* 2020;10:e042453. [PubMed doi:10.1136/bmjopen-2020-042453](#)</jrn>
- <jrn>25 Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Syst Rev* 2019;1:CD009009. [PubMed doi:10.1002/14651858.CD009009.pub3](#)</jrn>
- <eref>26 Ministry of Health. Hormone testing – indications and appropriate use. <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/special-endocrine-testing></eref>
- <jrn>27 Layton JB, Kim Y, Alexander GC, Emery SL. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. *JAMA* 2017;317:1159-66. [PubMed doi:10.1001/jama.2016.21041](#)</jrn>
- <jrn>28 Schwartz LM, Woloshin S. Low “T” as in “template”: how to sell disease. *JAMA Intern Med* 2013;173:1460-2. [PubMed doi:10.1001/jamainternmed.2013.7579](#)</jrn>
- <jrn>29 Dubin JM, Jesse E, Fantus RJ, et al. Guideline-discordant care among direct-to-consumer testosterone therapy platforms. *JAMA Intern Med* 2022;182:1321-3. [PubMed doi:10.1001/jamainternmed.2022.4928](#)</jrn>
- <jrn>30 Wackerbarth JJ, Fantus RJ, Darves-Bornoz A, et al. Examining online traffic patterns to popular direct-to-consumer websites for evaluation and treatment of erectile dysfunction. *Sex Med* 2021;9:100289. [PubMed doi:10.1016/j.esxm.2020.100289](#)</jrn>
- <jrn>31 Morden NE, Woloshin S, Brooks CG, Schwartz LM. Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. *JAMA Intern Med* 2019;179:446-8. [PubMed doi:10.1001/jamainternmed.2018.6505](#)</jrn>
- <jrn>32 Rao PK, Boulet SL, Mehta A, et al. Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. *J Urol* 2017;197:1121-6. [PubMed doi:10.1016/j.juro.2016.10.063](#)</jrn>
- <eref>33 American Urological Association. Testosterone deficiency guideline. 2024. <https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline></eref>
- <eref>34 US Food and Drug Administration. FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 2019. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due></eref>
- <jrn>35 Power M, Fell G, Wright M. Principles for high-quality, high-value testing. *Evid Based Med* 2013;18:5-10. [PubMed doi:10.1136/eb-2012-100645](#)</jrn>
- <jrn>36 Woloshin S, Kramer B. Overdiagnosis: it’s official. *BMJ* 2021;375:n2854. [PubMed doi:10.1136/bmj.n2854](#)</jrn>

- <jrn>37 LeeVan E, Pinsky P. Predictive performance of cell-free nucleic acid-based multi-cancer early detection tests: a systematic review. *Clin Chem* 2024;70:90-101. [PubMed doi:10.1093/clinchem/hvad134](#)</jrn>
- <eref>38 US Preventive Services Task Force. A and B recommendations. 2024. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations></eref>
- <eref>39 Galleri. Blood test for cancer screening. Galleri test. 2021. <https://www.galleri.com/></eref>
- <eref>40 Lee L. A moment to celebrate in our potentially revolutionary cancer blood tests trial. NHS England blog, 18 Jul 2022. <https://www.england.nhs.uk/blog/a-moment-to-celebrate-in-our-potentially-revolutionary-cancer-blood-tests-trial/></eref>
- <jrn>41 Schrag D, Beer TM, McDonnell CH 3rd, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. *Lancet* 2023;402:1251-60. [PubMed doi:10.1016/S0140-6736\(23\)01700-2](#)</jrn>
- <jrn>42 Deeks JJ, Ashby D, Takwoingi Y, et al. Lessons to be learned from test evaluations during the COVID-19 pandemic: RSS Working Group's report on diagnostic tests. *J R Stat Soc Ser A Stat Soc* 2024;187:659-709. [doi:10.1093/jrsssa/qnae053](#) .</jrn>
- <jrn>43 Ngoc BV, Majam M, Green K, et al. Acceptability, feasibility, and accuracy of blood-based HIV self-testing: A cross-sectional study in Ho Chi Minh City, Vietnam. *PLOS Glob Public Health* 2023;3:e0001438. [PubMed doi:10.1371/journal.pgph.0001438](#)</jrn>
- <jrn>44 Albarqouni L, Arab-Zozani M, Abukmail E, et al. Overdiagnosis and overuse of diagnostic and screening tests in low-income and middle-income countries: a scoping review. *BMJ Glob Health* 2022;7:e008696. [PubMed doi:10.1136/bmjgh-2022-008696](#)</jrn>
- <jrn>46 Fiala C, Taher J, Diamandis EP. P4 medicine or O4 medicine? Hippocrates provides the answer. *J Appl Lab Med* 2019;4:108-19. [PubMed doi:10.1373/jalm.2018.028613](#)</jrn>
- <jrn>47 Orth M, Vollebregt E, Trenti T, Shih P, Tollanes M, Sandberg S. Direct-to-consumer laboratory testing (DTCT): challenges and implications for specialists in laboratory medicine. *Clin Chem Lab Med* 2022;61:696-702. [PubMed doi:10.1515/cclm-2022-1227](#)</jrn>
- <eref>48 RCGP. RCGP Position statement on non-symptomatic self-tests. 2024. <https://www.rcgp.org.uk/representing-you/policy-areas/non-symptomatic-self-tests></eref>
- <jrn>49 Menkes DB, Mintzes B, Lexchin J. Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment. *BMJ Evid Based Med* 2024;bmjebm-2023-112622. [doi:10.1136/bmjebm-2023-112622](#). [PubMed](#)</jrn>
- <jrn>50 Gram EG, Macdonald H, Kramer B, Woloshin S; Preventing Overdiagnosis Scientific Committee. Call to improve transparent communication in direct-to-consumer test marketing. *BMJ Evid Based Med* 2024;29:213-4. [PubMed doi:10.1136/bmjebm-2024-112959](#)</jrn>
- <jrn>51 Rome BN. Direct-to-consumer drug company pharmacies. *JAMA* 2024;331:1003-4. [PubMed doi:10.1001/jama.2024.2911](#)</jrn>
- <jrn>52 DeFrank JT, Berkman ND, Kahwati L, Cullen K, Aikin KJ, Sullivan HW. Direct-to-consumer advertising of prescription drugs and the patient-prescriber

encounter: a systematic review. *Health Commun* 2020;35:739-46. [PubMed](#)
[doi:10.1080/10410236.2019.1584781](https://doi.org/10.1080/10410236.2019.1584781)</jrn>